This Giving Tuesday, make your gift count. Donate to the Northeast Ohio Liver Alliance by visiting our website http://liveralliance.org #LiverLeader #liveradvocates #grateful #givingtuesday2022 #liver
0
0
0
0
Hashtag
#liverleader
Advertisement · 728 × 90
This Giving Tuesday, make your gift count. Donate to the Liver Coalition of San Diego by visiting our website http://www.livercoalition.org
#LiverLeader #liveradvocates #grateful #givingtuesday2022 #liver
0
0
0
0
It's been real San Francisco. Already looking forward to #liver16 in Boston 11/11-15, 2016
#Liver15 #liverleader
0
0
0
0
Poster 2246: solithromycin pre-clinical data in STAM NASH mouse model #Liver15 #LiverLeader https://t.co/OnQrzksnXP
0
0
0
0
My take on treating acute #HCV with DAAs in light of data. Don't do it and wait 6 months then reassess #liver15 #LiverLeader
0
0
0
0
Dr. Terrault @UCSFTransplant delivers the annual tour de force that is the hepatitis debrief at #liver15 #LiverLeader
0
0
0
0
Five largest donors to @AASLDFoundation are @abbvie @GileadSciences @SalixPharma and Intercept #wecandomore #liver15 #LiverLeader
0
0
0
0
Dr. Africa: children with Zone 1 steatosis more likely to have advanced fibrosis, less likely to have steatohepatitis #Liver15 #LiverLeader
1
0
0
0
Dr. Hagstrom: diagnosis of severe liver disease occurred on average 14 years after diagnosis of diabetes. #Liver15 #LiverLeader
0
0
0
0
Dr. Hagstrom: 39y f/u of large Swedish conscript cohort shows BMI>25 in teens strongly assoc. w severe liver dz later #Liver15 #LiverLeader
0
0
0
0
Dr. Kleiner: NAS score v 2.0 coming. Unclear if yields more inter-observer variability. Do we still need steatosis? #Liver15 #LiverLeader
0
0
0
0
Dr. Kleiner: ballooning now classified as classical or none, severe or non, 0-4. New balloon score>2=NASH #Liver15 #LiverLeader #fattyliver
0
0
0
0
Late breaker: ELAD on life support, #sofosbuvir #velpatasvir pangenotypic cure for (almost) all. #emricasan promising #Liver15 #liverleader
0
0
0
0
Dr. Garcia-Tsao: 28d PO #emricasan reduces severe portal HTN in small group of compensated cirrhotics. ALT lower. #Liver15 #LiverLeader
0
0
0
0
Major issue with #HCV denial data: excluded patients ? more likely to be Medicaid recipients so could be even WORSE #Liver15 #liverleader
0
0
0
0
Dr. Lo Re: 16% denied #HCV treatment with 46% among Medicaid recipients mostly for "lack of medical necessity" #liverleader #Liver15
0
0
0
0
In ALLY-3+ extension to 16 wks didn't increase SVR12 in cirrhotics leading to question about whether 24 wks might #Liver15 #LiverLeader
0
0
0
0
Dr. Leroy: ALLY-3+ #daclatasvir #sofosbuvir+RBV for 12 or 16 wks gets 90% SVR12 overall and 86% in cirrhotic HCV GT3 #Liver15 #LiverLeader
0
0
0
0
Dr. Feld: in 2 patients who were not cured Y93H was detected at failure. Still role for #harvoni as 8 week data better #LiverLeader #liver15
0
0
0
0
Dr. Feld: ASTRAL-1 #sofosbuvir #velpatasvir 12 wk cures 99% GT1,4,5,6 regardless of experience, presence of cirrhosis #Liver15 #LiverLeader
0
0
0
0
Dr. Reich: plans for ELAD study in younger pts with less coagulopathy. Q&A focus on rationale & need for such study #Liver15 #LiverLeader
0
0
0
0
Dr. Reich: ELAD liver assist device in alchep fails to meet 28 & 91d survival endpoints incl. 2 deaths tied to device #Liver15 #LiverLeader
0
0
0
0
@AASLDPresident says new #AASLD rounded triangle logo represents inclusiveness, diversity and collaborative spirit #Liver15 #LiverLeader
0
0
0
0
Vit.E shows histology improvements in diabetics and non diabetics based on pooled data from PIVENS and FLINT trials #LiverLeader #liver15
0
0
0
0
Ph2. RCT of #NGM282 active in Primary Biliary Cholangitis w Incomplete response to UDCA. Higher AlkPhos did best #Liver15 #LiverLeader #PBC
0
0
0
0
Dr. Ratziu: #elafibranor fails to meet primary endpoint in NASH, better effect on more severe disease w/ 120 mg dose #Liver15 #LiverLeader
0
0
0
0
Dr. Chhatwal: modeling #HCV therapy. Rosy picture ideally. would take 60 yrs to treat all under current conditions #liver15 #LiverLeader
0
0
0
0
Dr. Coilly: #HCV antiviral therapy leads to improvement, withdrawal from Tx list in 16% pts, though 88% achieve SVR12 #Liver15 #LiverLeader
0
0
0
0
Dr. Terrault: PPI used associated with #harvoni virological failure. Reason unclear. Also 8 week option underutilized #Liver15 #LiverLeader
0
0
0
0
Dr. Terrault: real world HCV-TARGET data show SVR12 rates with 12 & 24 wks of #harvoni compared to clinical trials #Liver15 #LiverLeader
0
0
0
0